

## PRODUCT INFORMATION

<b>Clone ID</b>	DMC426
<b>Target</b>	TSLP
<b>Synonyms</b>	TSLP
<b>Host Species</b>	Rabbit
<b>Description</b>	Biotinylated Anti-TSLP antibody(DMC426); IgG1 Chimeric mAb
<b>Delivery</b>	2-3 weeks
<b>Uniprot ID</b>	Q969D9
<b>IgG type</b>	Rabbit/Human Fc chimeric IgG1
<b>Clonality</b>	Monoclonal
<b>Reactivity</b>	Human
<b>Applications</b>	Flow Cyt
<b>Recommended Dilutions</b>	Flow Cyt 1:100
<b>Purification</b>	Purified from cell culture supernatant by affinity chromatography
<b>Formulation &amp; Reconstitution</b>	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
<b>Storage &amp; Shipping</b>	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
<b>Background</b>	This gene encodes a hemopoietic cytokine proposed to signal through a heterodimeric receptor complex composed of the thymic stromal lymphopoietin receptor and the IL-7R alpha chain. It mainly impacts myeloid cells and induces the release of T cell-attracting chemokines from monocytes and enhances the maturation of CD11c( ) dendritic cells. The protein promotes T helper type 2 (TH2) cell responses that are associated with immunity in various inflammatory diseases; including asthma; allergic inflammation and chronic obstructive pulmonary disease. The protein is therefore considered a potential therapeutic target for the treatment of such diseases. In addition; the shorter (predominant) isoform is an antimicrobial protein; displaying antibacterial and antifungal activity against B. cereus; E. coli; E. faecalis; S. mitis; S. epidermidis; and C. albicans. Alternative splicing of this gene results in multiple transcript variants.
<b>Usage</b>	Research use only
<b>Conjugate</b>	Biotinylated
<b>DIMA Disclaimer</b>	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

